Sofia Ajeganova

Publikationer
CV
Populärvetenskap och samverkan

Artiklar

Article: THE LANCET RHEUMATOLOGY. 2024;6(7):e447-e459
Prevalence and target attainment oftraditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries
Bolla E; Semb AG; Kerola AM; Ikdahl E; Petri M; Pons-Estel GJ; Karpouzas GA; Sfikakis PP; Quintana R; Misra DP; Borba EF; Torre IG-DL; Popkova TV; Artim-Esen B; Troldborg A; Fragoso-Loyo H; Ajeganova S; Yazici A; Aroca-Martinez G; Direskeneli H; Ugarte-Gil MF; Mosca M; Goyal M; Svenungsson E; Macieira C; Hoi A; Lerang K; Costedoat-Chalumeau N; Tincani A; Mirrakhimov E; Colman IA; Danza A; Massardo L; Blagojevic J; Yilmaz N; Tegzova D; Yavuz S; Korkmaz C; Hachulla E; Alvarez MJM; Munoz-Louis R; Pantazis N; Tektonidou MG
Article: BMC RHEUMATOLOGY. 2023;7(1):23
Long-term fracture risk in rheumatoid arthritis: impact of early sustained DAS28-remission and restored function, progressive erosive disease, body mass index, autoantibody positivity and glucocorticoids. A cohort study over 10 years
Ajeganova S; Andersson M; Forslind K; Gjertsson I; Nyhall-Wahlin B-M; Svensson B; Hafstrom I
Article: BMC RHEUMATOLOGY. 2022;6(1):88
Erosion-free rheumatoid arthritis: clinical and conceptional implications-a BARFOT study
Svensson B; Andersson MLE; Gjertsson I; Hafstroem I; Ajeganova S; Forslind K
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2022;14:187-194
Misdiagnosis of Rheumatoid Arthritis in a Long-Term Cohort of Early Arthritis Based on the ACR-1987 Classification Criteria
Agelii ML; Hafstrom I; Svensson B; Ajeganova S; Forslind K; Andersson M; Gjertsson I
Article: ACR OPEN RHEUMATOLOGY. 2021;3(9):642-653
Effects of Atorvastatin on T-Cell Activation and Apoptosis in Systemic Lupus Erythematosus and Novel Simulated Interactions With C-Reactive Protein and Interleukin 6
Sun J; Panda PK; Samal SK; Ahuja R; Ajeganova S; Hafstrom I; Liu A; Frostegard J
Article: JOURNAL OF RHEUMATOLOGY. 2021;48(9):1371-1378
Team Rehabilitation in Inflammatory Arthritis Benefits Functional Outcomes Along With Improved Body Composition Associated With Improved Cardiorespiratory Fitness
Ajeganova S; Wornert M; Hafstrom I
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):201
Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events
Ajeganova S; Andersson MLE; Frostegard J; Hafstrom I
Article: LUPUS SCIENCE AND MEDICINE. 2021;8(1):e000454
Patients with SLE have higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and antiphospholipid syndrome: a case-control study over 10 years
Ajeganova S; Hafstrom I; Frostegard J
Article: ARTHRITIS RESEARCH & THERAPY. 2021;23(1):32
Low levels of PCSK9 are associated with remission in patients with rheumatoid arthritis treated with anti-TNF-α: potential underlying mechanisms
Frostegard J; Ahmed S; Hafstrom I; Ajeganova S; Rahman M
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2021;13:123-138
Influence of Age and Sex on Disease Course and Treatment in Rheumatoid Arthritis
Nilsson J; Andersson MLE; Hafstrom I; Svensson B; Forslind K; Ajeganova S; Agelii ML; Gjertsson I
Article: LUPUS. 2020;29(8):825-835
Proprotein convertase subtilisin kexin 9 is associated with disease activity and is implicated in immune activation in systemic lupus erythematosus
Liu A; Rahman M; Hafstrom I; Ajeganova S; Frostegard J
Article: ALLERGY. EUROPEAN JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. 2020;75(4):936-940
Biologicals in allergic diseases and asthma: Toward personalized medicine and precision health: Highlights of the 3rd EAACI Master Class on Biologicals, San Lorenzo de El Escorial, Madrid, 2019
Palomares O; Untersmayr E; Gutermuth J; Agache I; Ajeganova S; Bavbek S; Chan S; Jutel M; Quirce S; Schmid-Grendelmeier P; Schmidt-Weber C; Jose Torres M; Eiwegger T
Article: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2020;12:1759720X20974858
Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still's disease: when dosage matters in overcoming secondary therapy resistance
Ajeganova S; De Becker A; Schots R
Article: LUPUS SCIENCE AND MEDICINE. 2020;7(1):e000362
Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
Ajeganova S; Gustafsson T; Lindberg L; Hafstrom I; Frostegard J
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2019;48(6):431-438
Increased risk of osteoporotic fractures in Swedish patients with rheumatoid arthritis despite early treatment with potent disease-modifying anti-rheumatic drugs: a prospective general population-matched cohort study
Nyhall-Wahlin BM; Ajeganova S; Petersson IF; Andersson MLE
Article: JCI INSIGHT. 2019;4(9):126347
Oxidative hotspots on actin promote skeletal muscle weakness in rheumatoid arthritis
Steinz MM; Persson M; Aresh B; Olsson K; Cheng AJ; Ahlstrand E; Lilja M; Lundberg TR; Rullman E; Moller KA; Sandor K; Ajeganova S; Yamada T; Beard N; Karlsson BCG; Tavi P; Kenne E; Svensson CI; Rassier DE; Karlsson R; Friedman R; Gustafsson T; Lanner JT
Article: ARTHRITIS RESEARCH & THERAPY. 2019;21(1):45
Anti-citrullinated protein antibodies are associated with osteopenia but not with pain at diagnosis of rheumatoid arthritis: data from the BARFOT cohort
Hafstrom I; Ajeganova S; Forslind K; Svensson B
Article: OPEN ACCESS RHEUMATOLOGY: RESEARCH AND REVIEWS. 2019;11:207-217
A Swedish register-based, long-term inception cohort study of patients with rheumatoid arthritis - results of clinical relevance
Hafstrom I; Ajeganova S; Andersson MLE; Bala S-V; Bergman S; Bremander A; Forslind K; Malm K; Svensson B
Article: LUPUS. 2018;27(10):1670-1678
Autoantibody profiling reveals four protein candidate autoantigens associated with systemic lupus erythematosus
Frostegard J; Hellstrom C; Nilsson P; Frostegard AG; Ajeganova S
Article: CLINICAL RHEUMATOLOGY. 2018;37(7):1825-1834
Variation in pain related to systemic lupus erythematosus (SLE): a 7-year follow-up study
Waldheim E; Ajeganova S; Bergman S; Frostegard J; Welin E
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2018;36(3):428-433
Association between dietary and metabolic factors and IgM antibodies to phosphorylcholine and malondialdehyde in patients with systemic lupus erythematosus and population-based matched controls
Lourdudoss C; Ajeganova S; Frostegard J
Article: ATHEROSCLEROSIS. 2018;268:36-48
IgM antibodies against phosphorylcholine promote polarization of T regulatory cells from patients with atherosclerotic plaques, systemic lupus erythematosus and healthy donors
Sun J; Lundstrom SL; Zhang B; Zubarev RA; Steuer J; Gillgren P; Rahman M; Ajeganova S; Liu A; Frostegard J
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):115
The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical
Boeters DM; Mangnus L; Ajeganova S; Lindqvist E; Svensson B; Toes REM; Trouw LA; Huizinga TWJ; Berenbaum F; Morel J; Rantapaa-Dahlqvist S; van der Helm-van Mil AHM
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(4):716-720
Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present
Derksen VFAM; Ajeganova S; Trouw LA; van der Helm-van Mil AHM; Hafstrom I; Huizinga TWJ; Toes REM; Svensson B; van der Woude D
Article: ARTHRITIS RESEARCH & THERAPY. 2017;19(1):44
Effect of FCGR polymorphism on the occurrence of late-onset neutropenia and flare-free survival in rheumatic patients treated with rituximab
Ajeganova S; Tesfa D; Hgglund H; Fadeel B; Vedin I; Zignego AL; Palmblad J
Article: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(1):112-118
The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor
Ajeganova S; van Steenbergen HW; Verheul MK; Forslind K; Hafstrom I; Toes REM; Huizinga TWJ; Svensson B; Trouw LA; van der Helm-van Mil AHM
Article: ARTHRITIS RESEARCH & THERAPY. 2016;18(1):285
Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study
van Wesemael TJ; Ajeganova S; Humphreys J; Terao C; Muhammad A; Symmons DPM; MacGregor AJ; Hafstrom I; Trouw LA; van der Helm-van Mil AHM; Huizinga TWJ; Mimori T; Toes REM; Matsuda F; Svensson B; Verstappen SMM; van der Woude D
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(11):1924-1932
Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts
Ajeganova S; Humphreys JH; Verheul MK; van Steenbergen HW; van Nies JAB; Hafstrom I; Svensson B; Huizinga TWJ; Trouw LA; Verstappen SMM; van der Helm-van Mil AHM
Article: SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2016;45(6):448-455
Persistently active disease is common in patients with rheumatoid arthritis, particularly in women: a long-term inception cohort study
Svensson B; Andersson MLE; Forslind K; Ajeganova S; Hafstrom I
Article: JOURNAL OF REHABILITATION MEDICINE. 2016;48(8):711-718
A FOUR-WEEK TEAM-REHABILITATION PROGRAMME IN A WARM CLIMATE DECREASES DISABILITY AND IMPROVES HEALTH AND BODY FUNCTION FOR UP TO ONE YEAR: A PROSPECTIVE STUDY IN SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES
Ajeganova S; Wornert M; Hafstrom I
Article: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(5):867-873
Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms
Ajeganova S; van Steenbergen HW; van Nies JAB; Burgers LE; Huizinga TWJ; van der Helm-van Mil AHM
Article: ARTHRITIS RESEARCH & THERAPY. 2015;17(1):84
Bone mineral density and carotid atherosclerosis in systemic lupus erythematosus: a controlled cross-sectional study
Ajeganova S; Gustafsson T; Jogestrand T; Frostegard J; Hafstrom I
Article: BMJ OPEN. 2014;4(4):e004259
Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial
Ajeganova S; Svensson B; Hafstrom I
Article: JOURNAL OF RHEUMATOLOGY. 2013;40(12):1958-1966
Disease Factors in Early Rheumatoid Arthritis Are Associated with Differential Risks for Cardiovascular Events and Mortality Depending on Age at Onset: A 10-year Observational Cohort Study
Ajeganova S; Andersson MLE; Frostegard J; Hafstrom I
Article: ARTHRITIS CARE AND RESEARCH. 2013;65(1):78-87
Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long-term followup from disease onset
Ajeganova S; Andersson ML; Hafstrom I
Article: JOURNAL OF RHEUMATOLOGY. 2012;39(6):1146-1154
Carotid Atherosclerosis, Disease Measures, Oxidized Low-density Lipoproteins, and Atheroprotective Natural Antibodies for Cardiovascular Disease in Early Rheumatoid Arthritis - An Inception Cohort Study
Ajeganova S; de Faire U; Jogestrand T; Frostegard J; Hafstroem I
Article: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY. 2011;29(6):942-950
Effect of biological therapy on levels of atheroprotective antibodies against phosphorylcholine and apolipoproteins in rheumatoid arthritis: a one-year study
Ajeganova S; Fiskesund R; de Faire U; Hafstrom I; Frostegard J
Article: RHEUMATOLOGY. 2011;50(10):1785-1793
Longitudinal levels of apolipoproteins and antibodies against phosphorylcholine are independently associated with carotid artery atherosclerosis 5 years after rheumatoid arthritis onset-a prospective cohort study
Ajeganova S; Ehrnfelt C; Alizadeh R; Rohani M; Jogestrand T; Hafstrom I; Frostegard J
Article: ARTHRITIS & RHEUMATOLOGY. 2011;63(8):2209-2214
Late-Onset Neutropenia Following Rituximab Therapy in Rheumatic Diseases: Association With B Lymphocyte Depletion and Infections
Tesfa D; Ajeganova S; Hagglund H; Sander B; Fadeel B; Hafstrom I; Palmblad J
Visa fler

Alla övriga publikationer

Letter: ARTHRITIS & RHEUMATOLOGY. 2018;70(12):2096-2097
Anti-Carbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritis-A Replication Study in Three Cohorts: Comment on the Article by Truchetet et al
Derksen VFAM; Westerlind H; Saevarsdottir S; Ajeganova S; Trouw LA; Huizinga TWJ; van der Helm-van Mil AHM; Knevel R; van der Woude D
Review: THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE. 2017;9(10):249-262
Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations
Ajeganova S; Huizinga T
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2017;76(7):e17
Disease-modifying treatment in rheumatoid arthritis: treat early and do not forget to try to taper and stop
Ajeganova S; van der Helm-van Mil AHM
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2016;75(4):e14-EU5
Evaluation of the association between anticarbamylated protein antibodies and the longitudinal course of functional ability in rheumatoid arthritis
Ajeganova S; Svensson B; Huizinga TWJ; van der Helm-van Mil AHM; van Steenbergen HW
Letter: ANNALS OF THE RHEUMATIC DISEASES. 2015;74(1):e3
The effects of rheumatoid factor and anticitrullinated peptide antibodies on bone erosions in rheumatoid arthritis
van Steenbergen HW; Ajeganova S; Forslind K; Svensson B; van der Helm-van Mil AHM
Editorial comment: NATURE REVIEWS. RHEUMATOLOGY. 2015;11(1):8-9
Seronegative and seropositive RA: alike but different?
Ajeganova S; Huizinga TWJ
Letter: JOURNAL OF RHEUMATOLOGY. 2013;40(3):337-338
Prognosis Factors for Cardiovascular Events in Patients with Rheumatoid Arthritis: Multivariate Analysis Is Indispensable Reply
Ajeganova S; Hafstrom I
Thesis / dissertation: 2012
Addressing cardiovascular risk factors and therapy effects in rheumatoid arthritis : implications for atherosclerosis and cardiovascular disease
Ajeganova, Sofia
Letter: ARTHRITIS & RHEUMATOLOGY. 2012;64(2):597
Alternative explanations for development of late-onset neutropenia in rituximab-treated rheumatic disease patients: comment on the article by Tesfa et al Reply
Tesfa D; Ajeganova S; Hafstrom I; Palmblad J

Anställningar

Anknuten till Forskning, Medicin, Huddinge, Karolinska Institutet, 2022-2025

Examina och utbildning

Medicine Doktorsexamen, Institutionen för medicin, Huddinge, Karolinska Institutet, 2013

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI